Nicole White
Corporate Officer/Principal en ASSEMBLY BIOSCIENCES, INC. .
Fortuna: 171 716 $ al 30/04/2024
Cargos activos de Nicole White
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 17/11/2020 | - |
Historial de carrera de Nicole White
Antiguos cargos conocidos de Nicole White.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | 01/05/2018 | 01/11/2020 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/10/2015 | 01/04/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/03/2009 | 01/10/2015 |
Formación de Nicole White.
| University of California, Irvine | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Nicole White
- Experiencia